Explore 3 Stock Ideas & Industry Insights Download Free Report

FibroBiologics, Inc. Common Stock

Company price
0.9766 USD -0.02 ( 1.93%)
Last update at 2026-11-12T15:23:00Z
VOLUME
6371
Market Cap
10.02M

Momentum Score

…

FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis. It also develops early-stage research products, including CYTER915 to treat the human longevity; and TCB190 for the treatment of certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.93
Low
1.01
High
52 Week Price Range
0.62
Low
12.40
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Public filings and disclosures for FibroBiologics, Inc. are limited; available material identifies it as a clinical-stage biotechnology company focused on biologic therapies. Long-term growth may depend on clinical trial progress, regulatory milestones, strategic partnerships and commercialization of any approved therapies, which could support appeal to investors seeking exposure to early-stage biotech upside.

Key risks include clinical and regulatory failure, a short operating history with limited public disclosure, the need for additional financing that may dilute shareholders, and low trading liquidity.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
1.00
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.39
ROE
-660.08%
Net Debt
-2.48M
ROCE
-234.63%
Diluted EPS TTM
-4.68

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax -18.65M -11.16M -16.48M -5.12M -1.58M
Net income -18.65M -11.16M -16.48M -5.12M -1.58M
Selling general administrative 9.24M 9.23M 6.52M 3.32M 1.06M
Selling and marketing expenses - - 0.69M - -
Gross profit -0.83M -0.57M -0.44M - -
Reconciled depreciation 0.83M 0.57M 0.44M 0.09M 0.00M
Ebit -18.44M -11.14M -16.34M - -
Ebitda -17.61M -10.57M -15.90M - -
Depreciation and amortization 0.83M 0.57M 0.44M - -
Operating income -16.65M -13.74M -8.89M -4.47M -1.58M
Other operating expenses 16.65M 13.74M 8.89M - -
Interest expense 0.20M 0.02M 0.15M 0.65M 0.00M
Interest income 0.25M 0.25M 0.00M - -
Net interest income 0.04M 0.23M -0.15M -0.65M -0.00M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 15.82M 13.74M 8.89M 4.47M 1.58M
Cost of revenue 0.83M 0.57M 0.44M - -
Total other income expense net -2.00M 2.58M -7.60M - -
Net income from continuing ops -18.65M -11.16M -16.48M -5.12M -1.58M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 9.62M 16.45M 11.82M 4.82M 0.47M
Other current assets 1.46M 0.24M 0.05M 0.03M 0.02M
Total liab 3.46M 13.71M 10.57M 8.82M 1.76M
Total stockholder equity 6.16M 2.73M 1.25M -4.00M -1.29M
Other current liab 0.11M 0.46M 7.38M 0.54M -
Common stock 0.00M - 0.00M - -
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings -54.16M -35.52M -24.36M -7.87M -2.75M
Cash 4.89M 13.98M 9.16M 2.27M 0.41M
Total current liabilities 1.76M 12.73M 9.18M 7.07M 1.76M
Net debt -2.48M -3.43M -7.42M 3.19M 0.89M
Short term debt 0.71M 9.57M 0.36M - -
Short long term debt - 9.17M - 5.45M 1.30M
Short long term debt total 2.41M 10.55M 1.75M - -
Other stockholder equity 60.32M 38.25M 25.61M - -
Total current assets 6.35M 14.23M 9.21M 2.62M 0.47M
Accounts payable 0.94M 2.70M 1.44M 0.76M 0.23M
Accumulated other comprehensive income - - 0.00M - -
Non currrent assets other 0.05M - - - -
Non current assets total 3.27M 2.22M 2.61M 2.20M 0.00M
Capital lease obligations 2.41M 1.39M 1.75M 2.07M 0.00M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Investments - -0.18M -0.49M 0.00M -
Total cashflows from investing activities -0.26M -0.18M -0.49M - -
Net borrowings 0.97M 9.40M 0.30M - -
Total cash from financing activities 7.57M 16.91M 13.79M 5.92M 1.82M
Net income -18.65M -11.16M -16.48M -5.12M -1.58M
Change in cash -9.09M 4.82M 6.90M 1.86M 0.41M
Begin period cash flow 13.98M 9.16M 2.27M 0.41M 0.00M
End period cash flow 4.89M 13.98M 9.16M 2.27M 0.41M
Total cash from operating activities -16.39M -11.90M -6.40M -4.07M -1.41M
Issuance of capital stock 6.59M 7.51M 16.14M 2.15M 0.00M
Depreciation 0.83M 0.57M 0.44M 0.09M 0.00M
Other cashflows from financing activities - 9.40M 13.49M - -
Capital expenditures 0.26M 0.18M 0.49M 0.00M 0.00M
Change in working capital -3.31M 0.56M 0.49M 0.31M 0.17M
Stock based compensation 2.69M 2.22M 1.76M 0.27M 0.00M
Other non cash items 2.05M -4.09M 7.39M 0.39M -
Free cash flow -16.66M -12.09M -6.90M -4.07M -1.41M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
FBLG
FibroBiologics, Inc. Common Stock
-0.02
1.93%
0.98 - - - 2.25
NVO
Novo Nordisk A/S
0.98
2.41%
41.63 41.58 31.15 2.13 32.99
VRTX
Vertex Pharmaceuticals Inc
-2.37
0.43%
544.66 30.22 24.27 10.36 6.50
REGN
Regeneron Pharmaceuticals Inc
-2.77
0.29%
956.64 29.07 20.12 7.57 3.82
ARGNF
argenx SE
-
-%
900.30 45.77 31.25 13.84 7.12

Profile*

FibroBiologics, Inc. Common Stock

FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis. It also develops early-stage research products, including CYTER915 to treat the human longevity; and TCB190 for the treatment of certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.

455 East Medical Center Boulevard, Houston, TX, United States, 77598

281 671 5150

15

Name Title Year Born
Mr. Peter O'Heeron Founder, Chairman & CEO 1964
Mr. Mark C. Andersen C.F.A., CPA, M.B.A. Chief Financial Officer 1972
Dr. Hamid Khoja Ph.D. Chief Scientific Officer 1970
Mr. Ruben A. Garcia General Counsel NA
Mr. Peter O'Heeron Founder, Chairperson & CEO 1964
Mr. Ruben A. Garcia J.D. General Counsel 1978
Mr. Ruben A. Garcia J.D. General Counsel 1977

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…